About EP300-interacting inhibitor of differentiation 3
EP300-interacting inhibitor of differentiation 3 (EID3) is a protein
from Homo sapiens identified by UniProt accession
Q8N140, 333 residues long.
MolForge cross-references it against 0 known binders and
15 disease associations.
Target properties
| Protein name | EP300-interacting inhibitor of differentiation 3 |
|---|
| UniProt accession | Q8N140 |
|---|
| Gene | EID3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 333 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (15)
Diseases linked to this target (Open Targets).
- breast adenocarcinoma · score 0.23
- esophageal cancer · score 0.14
- genetic disorder · score 0.12
- cancer · score 0.02
- infection · score 0.01
- infect · score 0.01
- glioblastoma multiforme · score 0.01
- hepatocellular carcinoma · score 0.01
- neoplasm · score 0.01
- IGA glomerulonephritis · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8N140-F1 | alphafold | PREDICTED | 72.98 | — |
Amino-acid sequence (333 residues)
MKMDVSVRAA GCSDDLSSGE ADVDPKLLEL TADEEKCRSI RRQYRQLMYC VRQNREDIVS SANNSLTEAL EEANVLFDGV SRTREAALDA RFLVMASDLG KEKAKQLNSD MNFFNQLAFC DFLFLFVGLN WMEGDPDKLS DCDDSIALSF WKAIEKEATS WMVKAETFHF VFGSFKLERS APKPRLEHQK KVRKMEENGN MPTKLQKLDL SSYPEATEKN VERILGLLQT YFRKYPDTPV SYFEFVIDPN SFSRTVENIF YVSFIVRDGF ARIRLDEDRL PILEPMNVNQ MGEGNDSSCH GRKQGVISLT LQEWKNIVAA FEISEAMITY SSY
Explore EP300-interacting inhibitor of differentiation 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets